InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
73.70
(
-0.05%
)
Bitcoin
62,924.98
(
-0.64%
)
Post# of 253199
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120482
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 07/24/2020 11:33:08 AM

Friday, July 24, 2020 11:33:08 AM

Post# of 253199
ANNX IPOs 16.96M* shares @17.00:

https://www.globenewswire.com/news-release/2020/07/24/2067083/0/en/Annexon-Announces-Pricing-of-Initial-Public-Offering.html

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye.

…The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders.

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up